I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $396.57M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Acuity |
Philadelphia |
10/7/04 |
$15 |
The Series B financing was led by Psilos Group Managers, and included other new investors Johnson & Johnson Development Corp., Och-Ziff Capital Management Group, Diamond Capital Corp. and Trans-Science Inc.; existing investors also participated |
Argenta |
Harlow, UK |
10/4/04 |
£5.9 (US$10.5) |
Following the merger of Argenta and Etiologics Ltd., the merged firm got the investment from MVM Ltd., 3i, ABN AMRO Capital, Genavent and TTP Ventures |
Arpida Ltd. |
Basel, Switzerland |
10/15/04 |
CHF33 (US$27) |
The financing was made as Arpida completed its acquisition of Combio A/S; details on the financing, which followed a CHF51.3M Series C round in May, were not disclosed |
Attana AB |
Stockholm, Sweden |
10/15/04 |
€1.3 (US$1.64) |
The investment came from Carl Bennet AB and Ostersjostiftelsen |
Aureus |
Paris |
10/15/04 |
€3 (US$3.75) |
New investors OTC Asset Management and AXA Private Equity joined existing investors BIOAM and CDC Enterprises-FP Gestion in the financing round |
Biomax |
Martinsried, Germany |
10/12/04 |
€2.25 (US$2.8) |
Among the venture capital companies investing in the deal were BayBG, ECOS and S-UBG Bayern |
BioXell SpA |
Milan, Italy |
10/20/04 |
€23 (US$29.3) |
The third-round financing was led by BB Biotech and included NIF Ventures and QVentures, as well as existing shareholders MPM Capital, Index Ventures, AlpInvest Partners, Life Science Partners and Investimenti Piccole Imprese |
Catalyst |
South San Francisco |
10/28/04 |
$10.3 |
Sofinnova Ventures led the Series A financing, which also included Burrill and Co., RCT Bioventures and Novartis Venture Fund |
Chromatin |
Chicago |
10/27/04 |
$7.3 |
New investors in the Series B financing were the National Corn Growers Association, Illinois Ventures and Unilever Technology Ventures; returning investors were Burrill & Co., Venture Investors and Foragen |
Clinical |
Natick, Mass. |
10/21/04 |
$7.5 |
Oxford Bioscience Partners led the Series A financing, which included Rock Maple Ventures, Fletcher Spaght Venture Partners and a group of individual investors led by Jean "Coco" Montagu |
Genetix |
Cambridge, Mass. |
10/6/04 |
$12 |
The financing round was led TVM Techno Venture Management and included ABN AMRO Capital and Easton-Hunt Capital Partners |
Gloucester |
Cambridge, Mass. |
10/14/04 |
$29 |
The Series B financing was led by Prospect Venture Partners and co-led by ProQuest Investments and Rho Ventures; also participating were CIBC Capital Partners and Apple Tree Partners |
Innodia Inc. |
Montreal |
10/20/04 |
C$13 |
Innodia got a C$13M loan from Investissement Quebec; no payments are due for the first three years |
KAI |
South San Francisco |
10/26/04 |
$11 |
The second closing of a Series A round brought the round's total to $28M; the first tranche was completed in December 2003; investors were Skyline Ventures, InterWest Partners, Intersouth Partners, Delphi Ventures, Thomas Weisel Venture Partners and MDS Capital |
Leuchemix |
Newport Beach, Calif. |
10/4/04 |
$4 |
The CombiMatrix Group of Acacia Research Corp. will provide Lechemix $4M over two years in exchange for a one-third stake in the company |
MacroGenics |
Rockville, Md. |
10/15/04 |
$30.5 |
Alta Partners and TPG Ventures led the Series B financing, which also included Mithra Group, Red Abbey Venture Partners and Emerging Technology Partners, in addition to current Series A investors InterWest Partners, MPM Capital, OrbiMed, Cogene BioTech Ventures, Vivo Ventures and Hunt Ventures |
Metabolon Inc. |
Research Triangle Park, N.C. |
10/13/04 |
$9 |
Metabolon raised $9M in two closings of its Series A round; among the investors were Sevin Rosen Funds, The Aurora Funds, The Trelys Funds and Alexandria Real Estate Equities |
Miikana |
Fremont, Calif. |
10/6/04 |
$3 |
Existing investors 5AM Ventures, Aravis Ventures, Novartis Venture Fund and Queensland Asset Management, as well as a private investor, participated in an extension of the Series A round, which now totals $7.25M |
Nitec Pharma |
Basel, Switzerland |
10/4/04 |
$10 |
Atlas Venture and Global Life Science Ventures led the Series A financing; Nitec recently was spun out of Merck KGaA |
Nucleonics |
Horsham, Pa. |
10/13/04 |
$2.7 |
Oxford Finance Corp. provided the company an equipment financing facility |
Othera |
Exton, Pa. |
10/22/04 |
$3 |
Othera completed its $16M Series B round with the additional $3M investment, which came from NJTC Venture Fund, Fletcher Spaght Ventures and Liberty Venture Partners; the first closing was in August |
Peakadilly NV |
Ghent, Belgium |
10/18/04 |
€2 |
The Flanders Interuniversity Institute for Biotechnology (VIB) and Ghent University formed the company; VIB put up most of the initial capital |
PharmAthene |
Annapolis, Md. |
10/12/04 |
$50 |
MPM Capital and Bear Stearns Health Innoventures co-led the Series B financing; HealthCare Ventures, the sole Series A investor, also participated |
Prostrakan |
Galashiels, UK |
10/25/04 |
£22 (US$40.6) |
The funding was provided by LMS, 3i, Innoven Partenaires, Quest for Growth, employees and others; the company was formed by the merger of ProSkelia SAS and Strakan Group Ltd. |
7TM Phama |
Horsholm, Denmark |
10/28/04 |
€6 (US$7.73) |
Investors in the third-round financing included Index Ventures, Alta Partners, Novo A/S and Dansk Innovationsinvestering |
TxCell |
Nice, France |
10/15/04 |
€10.5 (US$13.1) |
Investing the Series A financing were Auriga Partners, AXA Private Equity, BioAm, CDC, SPEF Venture, Inserm-Transfert and company founders and management |
Vanda |
Rockville, Md. |
10/18/04 |
$37M |
Investing in the Series B round were Domain Associates, Prospect Venture Partners, Rho Ventures and MedImmune Ventures Inc. |
Zelos |
Ottawa, Ontario |
10/5/04 |
C$7 (US$5.55) |
Seaflower Ventures, VenGrowth Capital Partners Inc. and Genesys Capital Partners exercised their option for a second tranche of a Series A round; BDC Venture Capital also invested; Zelos raised C$14M in the first tranche in March 2003 |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $24M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
Acadia |
Allergan Inc. |
ND |
Milestone payment |
Triggered by Allergan's filing of an IND on a small-molecule drug for neuropathic pain that is covered in their collaboration (10/26) |
AnorMED Inc. |
Shire Pharmaceuticals Group plc (UK) |
$18 |
Milestone payment |
Triggered by FDA approval of the phosphate binder Fosrenol, the rights to which AnorMED sold to Shire in March (10/27) |
Arena |
Merck & Co. Inc. |
$1 |
Milestone payment |
Triggered by a preclinical milestone in their October 2002 deal covering GPCR targets for cardiovascular disease (10/26) |
BioVision AG* |
Novo Nordisk A/S (Denmark) |
ND |
Milestone payment |
Triggered by undisclosed progress in the deal under which BioVision provides biomarker and read discovery services to Novo (10/27) |
Kinexis Inc.* |
Merck & Co. Inc. |
ND |
Milestone payment |
Triggered by progress in their collaboration on biologic target validation of a prokineticin receptor in central nervous system indications (10/19) |
Pharmacopeia |
Schering-Plough Corp. |
ND |
Milestone payment |
Triggered by Schering-Plough's decision to initiate preclinical development of a candidate from their collaboration in oncology (10/5) |
SkyePharma |
Endo |
$5 |
Milestone payment |
Triggered by satisfaction of FDA approval of DepoDur and SkyePharma's supply of launch quantities of the product (10/25) |
TransTech |
Novo Nordisk A/S (Denmark) |
ND |
Milestone payment |
Triggered by an undisclosed achievement in their July 2001 deal covering TTP's discovery technology applied to Novo targets (10/26) |
Vertex |
GlaxoSmithKline plc (UK) |
ND |
Milestone payment |
Triggered by GSK's initiation of a pilot Phase II trial of the HIV protease inhibitor VX-385 (640385) (10/25) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* = Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
TSE = Toronto Stock Exchange. | ||||
